- Home
- TOVX vs GRI Comparison
TOVX vs GRI Comparison
Compare TOVX & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- GRI
- Stock Information
- Founded
- TOVX 2001
- GRI 2018
- Country
- TOVX United States
- GRI United States
- Employees
- TOVX N/A
- GRI N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- GRI Health Care
- Exchange
- TOVX Nasdaq
- GRI Nasdaq
- Market Cap
- TOVX 3.8M
- GRI 3.2M
- IPO Year
- TOVX 2006
- GRI N/A
- Fundamental
- Price
- TOVX $0.43
- GRI $1.26
- Analyst Decision
- TOVX Hold
- GRI Strong Buy
- Analyst Count
- TOVX 1
- GRI 2
- Target Price
- TOVX N/A
- GRI $22.00
- AVG Volume (30 Days)
- TOVX 1.6M
- GRI 112.3K
- Earning Date
- TOVX 08-12-2025
- GRI 08-13-2025
- Dividend Yield
- TOVX N/A
- GRI N/A
- EPS Growth
- TOVX N/A
- GRI N/A
- EPS
- TOVX N/A
- GRI N/A
- Revenue
- TOVX N/A
- GRI N/A
- Revenue This Year
- TOVX N/A
- GRI N/A
- Revenue Next Year
- TOVX N/A
- GRI N/A
- P/E Ratio
- TOVX N/A
- GRI N/A
- Revenue Growth
- TOVX N/A
- GRI N/A
- 52 Week Low
- TOVX $0.40
- GRI $1.10
- 52 Week High
- TOVX $7.37
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- TOVX 33.63
- GRI 40.16
- Support Level
- TOVX $0.43
- GRI $1.28
- Resistance Level
- TOVX $0.46
- GRI $1.45
- Average True Range (ATR)
- TOVX 0.04
- GRI 0.11
- MACD
- TOVX 0.02
- GRI 0.03
- Stochastic Oscillator
- TOVX 15.54
- GRI 29.30
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.